CD40-activated B cells can efficiently prime antigen-specific naïve CD8 + T cells to generate effector but not memory T cells

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Mathieu, Mélissa ^a,b   Cotta Grand, Natacha ^a,b   Daudelin, Jean François ^a   Boulet, Salix ^a,b   Lapointe, Réjean ^b,c   Labrecque, Nathalie ^a,b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; PROTEIN BCL 6; TOLL LIKE RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL RENEWAL; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; EFFECTOR CELL; FEMALE; IMMUNIZATION; IN VIVO STUDY; LYSIS; MALE; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; SPLEEN CELL; ANIMAL; ANTIGEN PRESENTATION; C57BL MOUSE; CELL CULTURE; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LISTERIA MONOCYTOGENES; LISTERIOSIS; LYMPHOCYTE ACTIVATION; METABOLISM; T LYMPHOCYTE; TRANSGENIC MOUSE;

LISTERIA MONOCYTOGENES;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD40; B-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; IMMUNOLOGIC MEMORY; LISTERIA MONOCYTOGENES; LISTERIOSIS; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; T-LYMPHOCYTES;

EID: 84856164141     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030139     Document Type: Article

References (54)

1. Mescher MF, Curtsinger JM, Agarwal P, Casey KA, Gerner M, et al. (2006) Signals required for programming effector and memory development by CD8+ T cells. Immunol Rev 211: 81-92.
2. Badovinac VP, Messingham KA, Jabbari A, Haring JS, Harty JT, (2005) Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination. Nat Med 11: 748-756.
3. Lacombe MH, Hardy MP, Rooney J, Labrecque N, (2005) IL-7 receptor expression levels do not identify CD8+ memory T lymphocyte precursors following peptide immunization. J Immunol 175: 4400-4407.
4. Joshi NS, Cui W, Chandele A, Lee HK, Urso DR, et al. (2007) Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity 27: 281-295.
5. Lopez JA, Bioley G, Turtle CJ, Pinzon-Charry A, Ho CS, et al. (2003) Single step enrichment of blood dendritic cells by positive immunoselection. J Immunol Methods 274: 47-61.
6. Eynon EE, Parker DC, (1992) Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens. J Exp Med 175: 131-138.
7. Lassila O, Vainio O, Matzinger P, (1988) Can B cells turn on virgin T cells? Nature 334: 253-255.
8. Ronchese F, Hausmann B, (1993) B lymphocytes in vivo fail to prime naive T cells but can stimulate antigen-experienced T lymphocytes. J Exp Med 177: 679-690.
9. Raimondi G, Zanoni I, Citterio S, Ricciardi-Castagnoli P, Granucci F, (2006) Induction of peripheral T cell tolerance by antigen-presenting B cells. I. Relevance of antigen presentation persistence. J Immunol 176: 4012-4020.
10. Raimondi G, Zanoni I, Citterio S, Ricciardi-Castagnoli P, Granucci F, (2006) Induction of peripheral T cell tolerance by antigen-presenting B cells. II. Chronic antigen presentation overrules antigen-presenting B cell activation. J Immunol 176: 4021-4028.
11. Fuchs EJ, Matzinger P, (1992) B cells turn off virgin but not memory T cells. Science 258: 1156-1159.
12. Gilbert KM, Weigle WO, (1994) Tolerogenicity of resting and activated B cells. J Exp Med 179: 249-258.
13. Parekh VV, Prasad DV, Banerjee PP, Joshi BN, Kumar A, et al. (2003) B cells activated by lipopolysaccharide, but not by anti-Ig and anti-CD40 antibody, induce anergy in CD8+ T cells: role of TGF-beta 1. J Immunol 170: 5897-5911.
14. Lapointe R, Bellemare-Pelletier A, Housseau F, Thibodeau J, Hwu P, (2003) CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 63: 2836-2843.
15. Schultze JL, Michalak S, Seamon MJ, Dranoff G, Jung K, et al. (1997) CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 100: 2757-2765.
16. von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, Hirano N, Anderson KS, et al. (2002) Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 99: 3319-3325.
17. Coughlin CM, Vance BA, Grupp SA, Vonderheide RH, (2004) RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood 103: 2046-2054.
18. Shen S, Xu Z, Qian X, Ding Y, Yu L, et al. (2007) Autogeneic rna-electroporated CD40-ligand activated b-cells from hepatocellular carcinoma patients induce CD8+ T-cell responses ex vivo. Exp Oncol 29: 137-143.
19. Ahmadi T, Flies A, Efebera Y, Sherr DH, (2008) CD40 Ligand-activated, antigen-specific B cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class I- and class II-binding peptides. Immunology 124: 129-140.
20. Kondo E, Gryschok L, Klein-Gonzalez N, Rademacher S, Weihrauch MR, et al. (2009) CD40-activated B cells can be generated in high number and purity in cancer patients: analysis of immunogenicity and homing potential. Clin Exp Immunol 155: 249-256.
21. von Bergwelt-Baildon M, Shimabukuro-Vornhagen A, Popov A, Klein-Gonzalez N, Fiore F, et al. (2006) CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants. Blood 107: 2786-2789.
22. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, et al. (1994) T cell receptor antagonist peptides induce positive selection. Cell 76: 17-27.
23. Kershaw MH, Hsu C, Mondesire W, Parker LL, Wang G, et al. (2001) Immunization against endogenous retroviral tumor-associated antigens. Cancer Res 61: 7920-7924.
24. Livingstone AM, Kuhn M, (1999) Dendritic cells need T cell help to prime cytotoxic T cell responses to strong antigens. Eur J Immunol 29: 2826-2834.
25. Porgador A, Yewdell JW, Deng Y, Bennink JR, Germain RN, (1997) Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 6: 715-726.
26. Ostiguy V, Allard EL, Marquis M, Leignadier J, Labrecque N, (2007) IL-21 promotes T lymphocyte survival by activating the phosphatidylinositol-3 kinase signaling cascade. J Leukoc Biol 82: 645-656.
27. Coles RM, Mueller SN, Heath WR, Carbone FR, Brooks AG, (2002) Progression of armed CTL from draining lymph node to spleen shortly after localized infection with herpes simplex virus 1. J Immunol 168: 834-838.
28. Bahjat KS, Liu W, Lemmens EE, Schoenberger SP, Portnoy DA, et al. (2006) Cytosolic entry controls CD8+-T-cell potency during bacterial infection. Infect Immun 74: 6387-6397.
29. Intlekofer AM, Takemoto N, Wherry EJ, Longworth SA, Northrup JT, et al. (2005) Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat Immunol 6: 1236-1244.
30. Leignadier J, Labrecque N, (2010) Epitope density influences CD8 memory T cell differentiation. PLoS One 5: e13740.
31. Schulze DH, Pease LR, Geier SS, Reyes AA, Sarmiento LA, et al. (1983) Comparison of the cloned H-2Kbm1 variant gene with the H-2Kb gene shows a cluster of seven nucleotide differences. Proc Natl Acad Sci U S A 80: 2007-2011.
32. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, et al. (1987) The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 329: 512-518.
33. Loyer V, Fontaine P, Pion S, Hetu F, Roy DC, et al. (1999) The in vivo fate of APCs displaying minor H antigen and/or MHC differences is regulated by CTLs specific for immunodominant class I-associated epitopes. J Immunol 163: 6462-6467.
34. Hand TW, Morre M, Kaech SM, (2007) Expression of IL-7 receptor alpha is necessary but not sufficient for the formation of memory CD8 T cells during viral infection. Proc Natl Acad Sci U S A 104: 11730-11735.
35. Intlekofer AM, Takemoto N, Kao C, Banerjee A, Schambach F, et al. (2007) Requirement for T-bet in the aberrant differentiation of unhelped memory CD8+ T cells. J Exp Med 204: 2015-2021.
36. Takemoto N, Intlekofer AM, Northrup JT, Wherry EJ, Reiner SL, (2006) Cutting Edge: IL-12 inversely regulates T-bet and eomesodermin expression during pathogen-induced CD8+ T cell differentiation. J Immunol 177: 7515-7519.
37. Banerjee A, Gordon SM, Intlekofer AM, Paley MA, Mooney EC, et al. (2010) Cutting edge: The transcription factor eomesodermin enables CD8+ T cells to compete for the memory cell niche. J Immunol 185: 4988-4992.
38. Kallies A, Xin A, Belz GT, Nutt SL, (2009) Blimp-1 transcription factor is required for the differentiation of effector CD8(+) T cells and memory responses. Immunity 31: 283-295.
39. Rutishauser RL, Martins GA, Kalachikov S, Chandele A, Parish IA, et al. (2009) Transcriptional repressor Blimp-1 promotes CD8(+) T cell terminal differentiation and represses the acquisition of central memory T cell properties. Immunity 31: 296-308.
40. Ichii H, Sakamoto A, Hatano M, Okada S, Toyama H, et al. (2002) Role for Bcl-6 in the generation and maintenance of memory CD8+ T cells. Nat Immunol 3: 558-563.
41. Ichii H, Sakamoto A, Kuroda Y, Tokuhisa T, (2004) Bcl6 acts as an amplifier for the generation and proliferative capacity of central memory CD8+ T cells. J Immunol 173: 883-891.
42. Ikeda H, Old LJ, Schreiber RD, (2002) The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 13: 95-109.
43. Blankenstein T, Qin Z, (2003) The role of IFN-gamma in tumor transplantation immunity and inhibition of chemical carcinogenesis. Curr Opin Immunol 15: 148-154.
44. Qin Z, Blankenstein T, (2000) CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 12: 677-686.
45. Dunn GP, Old LJ, Schreiber RD, (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21: 137-148.
46. Qin Z, Schwartzkopff J, Pradera F, Kammertoens T, Seliger B, et al. (2003) A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res 63: 4095-4100.
47. Barth RJ Jr, Mule JJ, Spiess PJ, Rosenberg SA, (1991) Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med 173: 647-658.
48. Prevost-Blondel A, Neuenhahn M, Rawiel M, Pircher H, (2000) Differential requirement of perforin and IFN-gamma in CD8 T cell-mediated immune responses against B16.F10 melanoma cells expressing a viral antigen. Eur J Immunol 30: 2507-2515.
49. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, et al. (2001) IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-1111.
50. Tuttle TM, McCrady CW, Inge TH, Salour M, Bear HD, (1993) gamma-Interferon plays a key role in T-cell-induced tumor regression. Cancer Res 53: 833-839.
51. Seki N, Brooks AD, Carter CR, Back TC, Parsoneault EM, et al. (2002) Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. J Immunol 168: 3484-3492.
52. Meunier MC, Delisle JS, Bergeron J, Rineau V, Baron C, et al. (2005) T cells targeted against a single minor histocompatibility antigen can cure solid tumors. Nat Med 11: 1222-1229.
53. Joshi NS, Kaech SM, (2008) Effector CD8 T cell development: a balancing act between memory cell potential and terminal differentiation. J Immunol 180: 1309-1315.
54. Vanden Bush TJ, Buchta CM, Claudio J, Bishop GA, (2009) Cutting Edge: Importance of IL-6 and cooperation between innate and adaptive immune receptors in cellular vaccination with B lymphocytes. J Immunol 183: 4833-4837.